Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients
Value Health
.
2014 Nov;17(7):A640.
doi: 10.1016/j.jval.2014.08.2307.
Epub 2014 Oct 26.
Authors
V P Retèl
1
,
L M G Steuten
2
,
J C Mewes
2
,
W H van Harten
2
Affiliations
1
Netherlands Cancer Institute, Amsterdam, The Netherlands.
2
University of Twente, Enschede, The Netherlands.
PMID:
27202291
DOI:
10.1016/j.jval.2014.08.2307
No abstract available